Objectives. The aim was to determine changes over time in work outcomes and investigate the predictive value of baseline personal and work-related factors on the evolution of work outcomes among employed patients with AS initiating etanercept.
Introduction
Patients with AS often struggle to meet the various demands of their job, which can lead to higher rates of withdrawal from employment, sick leave (absenteeism) and impairment while at work (presenteeism) compared with the general population [14] . As the disease symptoms often begin in late adolescence or early adulthood, restrictions in labour force participation can have substantial short-and long-term implications for both patients and society [5, 6] .
Published literature has shown that TNF-a inhibitors have beneficial effects on absenteeism or presenteeism in patients with AS, especially in comparison with pretreatment work limitations [710] . Caution is required because the majority of studies have been extensions of controlled trials, thus limiting the generalizability of the results in clinical practice. Additionally, these studies did not investigate variables predicting unfavourable work outcomes despite optimal treatment [8, 10, 11] . Work loss or continuing restrictions while undergoing treatment with biologics might be related to insufficient response to treatment or the presence of irreversible limitations in mobility (spinal damage), and also to personal or workrelated contextual factors that hamper successful worker participation, which has not been explored sufficiently. Understanding the baseline contextual factors that affect withdrawal from the labour force, absenteeism and presenteeism over time might help to provide a better understanding of the work-related life cycle of patients with AS, which might, in turn, be useful for identifying effective interventions to prevent early withdrawal from the labour force.
The objective of this study was to explore the evolution of employment status, absenteeism and presenteeism over 24 months in patients with AS who received etanercept treatment in a real-life observational setting. The secondary objectives were to assess the potential impact of personal and work-related contextual factors present at the initiation of etanercept treatment, in addition to disease-related factors, on these evolutions using predictive modelling.
Methods

Study design and patients
This was an open-label, observational study in 19 clinical practices across Belgium (ClinicalTrials.gov NCT014 21303). Patients were recruited between 30 October 2009 and 7 October 2011 and followed up for 24 months (the last follow-up visit was on 5 December 2013). The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, and the Ethics Committee at UZ Ghent reviewed and approved the study protocol. Written informed consent was obtained at the time of inclusion.
Detailed study methods have been described in the previously published analysis of the baseline data [12] . Briefly, in order to be eligible, patients had to be 518 years old, diagnosed with AS by a rheumatologist, in paid employment, capable of understanding and completing questionnaires, and have been scheduled by their physician to start etanercept treatment. In order to meet the Belgian reimbursement eligibility criteria, patients were required to: meet the modified New York criteria for the diagnosis of AS; have failed conventional therapy for AS; have a BASDAI score 54; have a CRP value higher than the upper limit of normal; have an inadequate response to two or more NSAIDs for at least 3 months; not have active or latent tuberculosis; and have a prescription for etanercept treatment from a board-certified rheumatologist. Patients were excluded if they had previously used TNF inhibitors or if they had initiated a procedure for eligibility for work disability or retirement. 
Assessments
Patients completed the Work Productivity and Activity Impairment for AS questionnaire at each visit [13] , in which the responses covered the 7 days before the visit. The resulting scores were used to define employment status over time and to calculate absenteeism (percentage of hours of work time missed because of AS) and presenteeism (percentage of restricted productivity while working attributable to AS). Before etanercept treatment (baseline), each patient filled out a questionnaire on personal and contextual factors relevant to work outcomes; this was based on existing questionnaires and work participation models and followed the biopsychosocial model proposed by the International Classification of Functioning, Disability and Health model, as detailed in the previously published analysis of baseline data from this study [12, 14] . Personal factors included age, sex, education and importance of job for quality of life, whereas work-related contextual factors were related to the profession, job control and autonomy, workplace characteristics and attitudes and support of colleagues. A full description of all the assessments and sources of the specific questions was reported in our previous publication [12] . A range of outcomes were assessed at baseline and at each patient visit, as follows: physician global assessment (range 010), BASDAI (range 010) [15] , BASFI (range 010) [16] , BASMI (010) [17] , BAS-G (010) and ASDAS using both the CRP and ESR methods [18] .
Statistical analysis
Results for quantitative variables were expressed as the mean and S.D. or as the median and interquartile range (IQR) for skewed distributions. Categorical variables were summarized as frequency tables. The distribution of employment time was analysed with respect to baseline factors by the Cox proportional hazard regression model. Associations were expressed by the hazard ratio (HR) and 95% CI. The effect of clinical and baseline personal and work-related contextual factors on the evolution of absenteeism and presenteeism over time was assessed by the generalized linear mixed model (GLMM). Absenteeism was displayed as a quantitative variable but analysed as an ordered categorical variable (no, 0%; partial, 199%; complete, 100%). This was necessary because the distribution of absenteeism was highly (positively) skewed (both first and second quartiles were equal to zero at all times) and could not be transformed to normality. Grouping of values into the three categories mentioned not only made sense but was also easier to analyse statistically as an ordinal outcome variable.
Statistically significant personal, work-related contextual and disease-related covariates at the univariate level were combined in a stepwise selection procedure to derive the best multivariate model. All analyses were carried out on the original dataset. Results were considered significant at the 5% critical level (P < 0.05). Data analyses were performed with SAS (version 9.4; SAS Institute) and S-PLUS (version 8.1; TIBCO Software Inc.) software.
Results
Patient population
Eighty patients with AS were originally screened and enrolled in the study (Fig. 1 ). The present analysis was based on 75 patients who had at least one follow-up visit after initiation of etanercept treatment. Among these 75 patients, 17 (22.7%) dropped out early from the study (five patients by 12 months, seven more by 18 months, and five by 24 months); a majority (64.7%) of them were lost to follow-up. One patient had the last visit outside the acceptable time window and was excluded from the statistical analysis.
The mean (S.D.) age was 38.1 (8.7) years and the median disease duration 10 (IQR: 5.215.6) years (Table 1) . Disease characteristics can be seen in Table 1 , and the distribution of personal and work-related contextual factors can be found in supplementary Table S1 , available at Rheumatology online. At 24 months, 51/57 patients (89.5%) were still receiving etanercept therapy.
Withdrawal from the labour force After 24 months, 11 (14.7%) of 75 patients had withdrawn permanently from the labour force, seven (9.3%) of them because of AS. Two of the 11 patients were also included in those who dropped out from the study. Four (5.3%) of the 75 patients were reported to be unemployed at some visits but were back at work afterwards. (Fig. 3A) . Completers (n = 58) and patients who dropped out (n = 17) had similar evolutions of absenteeism (P = 0.34). GLMM analysis of absenteeism as a time-related categorical outcome demonstrated a decrease in both partial and complete absenteeism within 6 months of treatment with etanercept (supplementary Table S2 , available at Rheumatology online), which was maintained up to 24 months. The baseline factors significantly associated with lower absenteeism over time were the quality of contact with colleagues and importance of the job for quality of life (Table 2 ), whereas higher absenteeism over time was associated with current smoking, having changed job in the past because of illness, higher BASDAI and higher absenteeism at baseline (Table 2) .
Combining significant baseline covariates in a multivariate analysis of the evolution of absenteeism showed that the importance of the job for quality of life was associated with lower absenteeism, whereas current smoking and BASDAI score were associated with higher absenteeism (Table 2; supplementary Fig. S1AC , available at Rheumatology online).
Presenteeism
Presenteeism also decreased as disease activity decreased and physical function improved over the course of etanercept treatment (Fig. 2) . Presenteeism decreased significantly from 49.4% (S.D. 22.9) at baseline to 28.0% (S.D. 22.4) at 6 months and remained stable thereafter, culminating with 24.9% (S.D. 20.4) at 24 months (Fig. 3B ). Completers and patients who dropped out had similar evolutions of presenteeism (P = 0.45).
GLMM analysis confirmed the significant effect of time on presenteeism values and showed that several baseline factors were individually associated with the evolution of presenteeism (Table 3) . Lower presenteeism over time was associated with male sex, baseline possibility of postponing work, quality of contact with colleagues and >50 workers in the company. Higher presenteeism was associated with higher age, longer time since first paid job, manual profession, higher BASMI, BASFI, BASDAI, BAS-G, ASDAS-CRP and ASDAS-ESR and with higher baseline presenteeism.
From a multivariate standpoint, sex (male) and >50 workers in the company were associated with lower presenteeism, whereas higher age, manual profession and higher baseline BASFI and BASDAI were associated with higher presenteeism over time (Table 3 ; supplementary Fig. S2AF , available at Rheumatology online).
Discussion
Identifying the role of contextual factors, personal as well as environmental, in an individual patient's work outcomes is becoming increasingly important when aiming to understand and improve work outcomes in patients with AS [12, 19, 20] . In the present study, several
FIG. 3 Evolution of work outcomes
A). Absenteeism, *P < 0.001 (GLMM analysis on categorical outcome); B). Presenteeism, *P < 0.0001 (GLMM analysis). Error bars represent standard error. GLMM: generalized linear mixed model.
FIG. 2 Changes over time in absenteeism, presenteeism and clinical variables shown as percentage values of baseline levels
Baseline values were assigned as 100%, and the figure shows percentage changes measured over time.
pre-treatment personal and work-related contextual factors and disease-related factors were predicted to have a marked influence on employment status, absenteeism and presenteeism over a 24-month treatment period.
In terms of insight into the influence of biologic treatment on the employment status of patients with AS over time, the majority of patients receiving etanercept treatment remained in employment over 24 months. Nonetheless, 9.3% of patients stopped work because of their AS despite receiving treatment. In a recent publication on the impact of AS over 12 years (since 1996) in Dutch patients in the OASIS cohort, the risk for withdrawal from employment was higher in patients with AS [2.9 times higher in males (95% CI: 1.2, 4.6) and 1.2 times higher in females (95% CI: À0.4, 2.9)] compared with the general population [21] . Higher age, Dutch residency, IBD, uveitis and higher BASDAI/BASFI were baseline and/ or time-varying predictors of adverse work outcomes over 12 years. The availability or gradual uptake of anti-TNFs in the last 6 years of follow-up did not influence this course, but patients had longstanding disease, and uptake of antiTNFs was low in the initial years [21] . In contrast, in the national database of the German Collaborative Arthritis Centres, a substantial increase in employment was seen from 2000 to 2012 in patients aged 4150 years and those aged 5160 years (+16 and +17%, respectively) [22] . Ageadjusted employment for women increased from 51% in 2000 to 56% in 2012, and from 54% to 71% in men over the same period [22] . Nevertheless, employment remained lower in patients with AS than in the general population. All of the above findings emphasize the need for medical professionals to recognize that receiving medical treatment does not resolve all the restrictions or problems that patients with AS face at work; that is, there are still contextual factors that affect work disability in patients. The role of contextual factors was not extensively explored in any of the abovementioned studies. The OMERACT worker productivity group, which recently published the results of a systematic literature review on the relationship between contextual factors and not being employed in patients with AS, reported that age demonstrated the strongest association with employment status, while a moderate association was seen with work accommodations, nature of work, workplace support (environmental factors) and related skills/abilities, such as work autonomy or coping (personal factors) [20] . However, most of these were cross-sectional studies and dated from the pre-biological therapy era.
In the present longitudinal dataset, absenteeism was reduced within 6 months of initiation of etanercept treatment (from 30.4% at baseline to 6.2% at 6 months), and the low level of absenteeism was maintained over 24 months. These results are in agreement with a previously published report that stated a decrease in the proportion of patients on sick leave from 28% before treatment with anti-TNFs to 12% after 12 months of treatment [8] . The mean number of days on sick leave has also been reported to decrease from 37.4 to 15.1 days [9] and from 15 to 0.91 days [7] after 12 months of anti-TNF treatment. In terms of elucidating the factors associated with absenteeism in the available literature, the OMERACT worker productivity group had identified too few studies to collate meaningful data on the impact of contextual factors on absenteeism [20] . Thus, the present study provides much-needed data on the influence of contextual factors on absenteeism in patients with AS, and supports both the OMERACT worker productivity group and the ICF framework, which highlighted the role of contextual factors in the evolution of work outcomes in patients with AS. In the present study, the quality of contact with colleagues and the importance of the job for quality of life led to lower absenteeism, suggesting that patients who are supported by colleagues and who value their job are more motivated to limit absence from work.
Presenteeism was also reduced within 6 months of initiation of etanercept treatment (from 49.4% at baseline to 28.0% at 6 months), and the reduction was maintained over 24 months. Lower presenteeism after the start of etanercept was associated with male sex, the ability to postpone work, better quality of contact with colleagues and larger numbers of workers at the work place. These results indicate that more flexibility at work and better support from colleagues could lower the impact of AS on work outcomes and should be encouraged for patients with AS. The results also showed that higher age and manual profession could lead to higher presenteeism. As neither flexibility at work nor quality of contact with colleagues was retained in the multivariate analysis, the negative impact of manual jobs is likely to be related to lower flexibility and lack of support from colleagues. Of the limited studies that explored the role of contextual factors in relation to presenteeism in patients with AS, in a study among 311 employed patients, female sex and helplessness were associated with higher presenteeism [23] .
Although the present study concentrated on work-related contextual factors, it is clear that worse disease in terms of higher BASDAI and or BASFI also plays a strong role in adverse work outcomes after 24 months. This is well known from numerous previous publications; the focus of the present study was the additional role of contextual factors. It is expected that initiating etanercept or any other TNF inhibitor in patients with AS will improve (decrease) their absenteeism and presenteeism as a result of improvement of inflammation. Nonetheless, our study shows that, given specific personal and work-related contextual factors known before treatment initiation, we can to some extent predict and discern which patients will improve their absenteeism and presenteeism differently compared with the average improvement expected with etanercept treatment only. As an example, when starting etanercept treatment in an older female manual worker of a small company, we can anticipate sustained higher presenteeism during treatment despite overall improvement of her condition.
In terms of study limitations, the sample size was small and limits the ability to compare withdrawal from work attributable to AS with that in the general population. Furthermore, the study reflects only conditions experienced by Belgian patients (contextual factors might differ in different countries/cultures; for example, attitudes of colleagues, or based on how much control people have on various factors, for example, workload). There are currently no data on systematic workplace variations across regions or cultures. Additionally, this study was limited by the lack of a comparator arm of patients who were not treated with biologics. Finally, it would have been interesting to have had information on other personal contextual factors, such as helplessness or coping. The real impact of treatment on work-related contextual factors over time could not be assessed in the present study; this could be investigated further to determine whether etanercept treatment might modify some of these.
In conclusion, although treatment with etanercept could not completely prevent withdrawal from labour, there were large improvements in absenteeism and presenteeism in patients with AS over the 2-year study period. A number of work-related contextual factors associated with these outcomes were identified, which require more attention when aiming to improve work participation further in patients with AS. Similar effects might be observed with other TNF inhibitors.
